Weight loss,adverse events,and loss to follow-up after gastric bypass in young versus older adults: A Scandinavian Obesity Surgery Registry study

Background

Young adults display particularly poor weight loss in behavioral obesity treatment; nonetheless, they have seldom been included in bariatric research.

杂交捕获法和PCR-RDB法检测妇女HPV感染的比较

Objective To compare hybrid capture-Ⅱ(HC2)to polymerase chain reaction(PCR)-reverse dot-blot(RDB)for detecting HPV infection in women.Methods HC2 method and PCR-RDB were applied to detecting human papillomaviral infection in female genital duct,and the test results were analyzed.Results Concordant results were found in 81.14%(400/493)samples(Kappa=0.63;95%CI,0.57-0.69).The high risk type HPV positive rate detected by PCR-RDB were 1.60%(3/187),29.85%(20/67),69.88%(58/83),86.52%(77/89)and 91.04%(61/67),respectively,when the HC2 RLU/CO of samples were＜1.00,1.00-9.99,10.00-99.99,100.00-999.99 and≥1000.00.Statistical differences were found among the five groups(χ2=289.3,P＜0.01).Cross reactions were found between HC2 high risk probe and HPV53,66,11,cp8304 and other genotypes.Conclusion There is good concordance between HC2 and PCR-RDB,though cross reaction exists in HC2.Relatively speaking,there are more influential factors for PCR-RDB.     

艾灸治疗恶性血液病化疗所致胃肠道反应的临床观察

目的观察艾灸治疗恶性血液病化疗所致胃肠道反应的临床效果。方法100例恶性血液病化疗患者随机分为艾灸组和对照组,每组各50例。艾灸组在化疗前0.5 h静脉推注欧贝针,并于化疗当天开始艾灸神阙穴、内关（双）和足三里（双）,持续3疗程共18 d;对照组在化疗前0.5 h静脉推注欧贝针,未接受艾灸疗法。结果艾灸组控制迟发性呕吐的有效率明显高于对照组（P〈0.05）。结论艾灸治疗恶性血液病化疗所致胃肠道反应疗效好,尤其对迟发性呕吐的效果佳。     

表柔比星联合多西他赛或紫杉醇治疗乳腺癌效果差异分析

目的探讨表柔比星联合多西他赛或紫杉醇治疗乳腺癌的效果差异。方法选取2018年2月至2019年7月本院收治的86例乳腺癌患者,根据动态随机分组法将其分为对照组(n=43)和观察组(n=43),对照组采用表柔比星联合紫杉醇治疗,观察组采用表柔比星联合多西他赛治疗,比较两组临床缓解率、1年内复发率、生存时间以及不良反应发生率。结果两组患者临床缓解率差异经统计学软件检验显示无统计学意义(P>0.05);观察组1年内复发率和不良反应发生率低于对照组,生存时间长于对照组,差异经统计学软件检验显示有统计学意义(P<0.05)。结论表柔比星联合多西他赛或紫杉醇对乳腺癌的治疗效果相近,但联合多西他赛的不良反应风险更低,还可延长患者生存时间。     

Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature

ABSTRACT

Background: Real-life data often highlight the side effects of certain drugs not previously reported in randomized controlled trials (RCTs).

Objective: To describe cutaneous inflammatory eruptions in psoriatic patients treated with an anti IL-17A agent (secukinumab or ixekizumab).

Methods: Retrospective analysis of a cohort of patients with chronic plaque psoriasis who started an anti IL-17A agent between September 2016-February 2019 and who developed cutaneous inflammatory eruptions during treatment. A systematic review of similar events reported in the literature was performed.

Results: Data of 468 patients were reviewed and 27 cutaneous inflammatory eruptions of 27 (5.8%) patients were collected. The eruptions appeared after a mean of 16.9 ± 17.0 weeks of therapy showing a classical acute eczema in 11 patients (40.7%), an atopic dermatitis-like rash in 11 patients (40.7%) and a psoriasiform eruption in 5 patients (18.5%). Histopathology of 12/27 cases showed epidermal spongiosis in all these variants.

Conclusion: We described the clinic-pathologic features of some eczematous eruptions occurring in psoriatic patients, 3–4 months after treatment initiation with an anti IL-17A agent. Further investigations are needed to explain this phenomenon, that might be defined a paradoxical adverse event, based upon the role of IL17 in eczema pathogenesis.     

Multicenter,open-label evaluation of hyperemia associated with use of bimatoprost in adults with open-angle glaucoma or ocular hypertension

This month-long multicenter, open-label study evaluated the onset and progression of hyperemia associated with bimatoprost 0.03% once daily in 39 patients with open-angle glaucoma or ocular hypertension. Current glaucoma medication(s) was either replaced with or augmented by bimatoprost. Previous users of bimatoprost were excluded. Primary outcome measures were mean hyperemia scale scores (ciliary, conjunctival, and episcleral, graded on a seven-point scale) and incidence of hyperemia. Secondary outcome measures were fluorescein staining, patient assessment of ocular redness (take-home diary), and patient and investigator evaluations. Patients were asked how troubled they were by their ocular redness. Investigators were asked if they would continue the patient on bimatoprost despite the hyperemia. Overall, the frequency and severity of hyperemia peaked approximately 1 day after the first instillation of bimatoprost and decreased consistently throughout the study, returning to near-baseline levels by day 28. At day 1, 84.6% of patients were hardly troubled or not troubled by their ocular redness; only 15.4% were somewhat or moderately troubled. Investigators indicated that they would continue bimatoprost therapy in 92.3% of the patients. Hyperemia did not represent a significant safety concern.     

Trimethoprim-sulfamethoxazole-induced aseptic meningitis: case report and literature review

Aseptic meningitis is a rare adverse drug reaction, reported with non-steroidal anti-inflammatory agents (NSAIDs) and with miscellaneous drugs such as trimethoprim-sulfamethoxazole (TMP-SMX). The most common clinical findings reported are fever, headache, stiffness and altered level of consciousness. We report a case of aseptic meningitis related to TMP-SMX ingestion that caused severe derangements of the patient's vital signs, requiring Intensive Care Unit admittance. The prompt diagnosis and discontinuation of the drug resulted in complete recovery. We examine the case according to the literature on this topic. We conclude that, since the signs and symptoms of this unusual drug reaction may mimic those of central nervous system infection, the clinician should consider this etiology when he is faced with a patient with suspected meningoencephalitis, especially if the latter has already been treated at home with unknown drugs. Further studies should investigate the pathogenetic mechanism of TMP-SMX-induced aseptic meningitis.     

时辰化疗不良反应观察及护理对策

目的 对比观察时辰化疗与常规化疗方法在肿瘤患者中的不良反应程度。方法 对108例肿瘤病人化疗后的不良反应进行程度评定。结果 时辰化疗所致不良反应远低于常规化疗方法。结论 时辰化疗可达到选择对癌细胞杀伤力强而正常组织毒性最小的时间给药的目的，临床疗效满意。     

护士对出入量的认知与记录准确性的相关性分析

记录液体出入量（简称出入量）是指将患者24h内的摄人量与排泄量详细地记录在护理记录单上，为临床了解病情，协助诊断，决定治疗方案提供重要依据。因而准确记录出入量是一项十分重要的基础护理工作。由于出入量所包含项目的多样性，在实践中记录出入量容易产生误差，存在着漏记、记量不准确等现象。为进一步分析出入量记录存在误差的原因，